Oncolytics Biotech

U.S. Patent Disclosures

tmcnet.com
14-Nov-2008
        

of Burlingame, Calif., received U.S. Patent No. 7,429,487, which covers the next generation of cells for producing rabbit monoclonal antibodies. Gemin X, of Malvern, Pa., received U.S. Patent No. 7,425,553, protecting the...

add comment

Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Research at CTOS Annual Meeting

finanznachrichten.de
14-Nov-2008 5 related
        

CALGARY, Nov. 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation authored by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled...

add comment
                   

Anti-cancer drugs’ efficacy virus found

asianage.com
08-Nov-2008
        

London: A Canadian researcher team says that the efficacy of anti-cancer drugs in destroying tumours, or in keeping them in check, may be improved with the aid of a virus called reovirus. Brad Thompson, CEO of Canadian company...

add comment
                   

Virus that improves anti-cancer drugs' efficacy unveiled

newstrackindia.com
08-Nov-2008 8 related
        

London, November 7 (ANI): A Canadian researcher team says that the efficacy of anti-cancer drugs in destroying tumours, or in keeping them in check, may be improved with the aid of a virus called reovirus.

add comment

Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call

finanznachrichten.de
05-Nov-2008 7 related
        

CALGARY, Nov. 5 /PRNewswire-FirstCall/ -- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), will host a conference call and webcast on Thursday, November 6, 2008 at 11:00...

add comment

Oncolytics Biotech Inc. Announces Decision To Pursue Phase II/III Pivotal Clinical Trial

medicalnewstoday.com
05-Nov-2008 27 related
        

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that it has made a decision to pursue a pivotal (Phase II/III) randomized trial using the combination of REOLYSIN(R) with paclitaxel/carboplatin in...

add comment

Forscher von Oncolytics Biotech Inc. präsentieren auf der Jahresversammlung von iSBTC ihre...

presseportal.de
03-Nov-2008 4 related
        

Calgary, Kanada, November 3 (ots/PRNewswire) - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) gab heute bekannt, dass sie in ihren britischen Phase-I- und Phase-II-Kombinationsstudien mit REOLYSIN (R) und...

add comment
                   

InPlay: Baidu.com announces $200 mln share repurchase program (Briefing.com)

yahoo.com
03-Nov-2008 9 related
        

7:49AM Constellation Energy provides update on liquidity and strategic initiatives 24.21 : Co provides an update on its previously announced plans to increase available liquidity and reduce risk in its commodities businesses....

add comment
                   

BIO Investor Forum Presenter Profiles

euroinvestor.co.uk
28-Oct-2008
        

BIO Investor Forum takes place October 29, 2008 - In February 2008 the Company announced positive results in a Phase IIa clinical study for amnestic MCI, a precursor to Alzheimer’s disease, showing statistically significant,...

add comment

Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN and Paclitaxel/Carboplatin...

drugs.com
26-Oct-2008
        

CALGARY, October 23, 2008 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. today announced that an abstract entitled "Phase I Trial of Oncolytic Reovirus (REOLYSIN(R)) in Combination with Carboplatin/Paclitaxel in Patients with...

add comment